Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Praxis Precision Medicines (NASDAQ:PRAX) is one of the 17 biotechnology stocks with more than 50% upside. On February 10, Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines (NASDAQ:PRAX) from $760 to $800. He maintained a Buy rating on the stock, which he believes offers more than 140% upside. Why Core Scientific Inc. (CORZ) Performed Worst On Tuesday? Sergey Nivens/Shutterstock.com Suneja highlighted his analysis and feedback from industry experts, which suggests uli ...